Impact of hormonal biomarkers on response to hormonal therapy
in advanced and recurrent endometrial cancer

J 2021

Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer

WEELDEN, van W. J., R. I. LALISANG, J. BULTEN, K. LINDEMANN, H. J. VAN BEEKHUIZEN et. al.

Basic information

Original name

Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer

Authors

WEELDEN, van W. J., R. I. LALISANG, J. BULTEN, K. LINDEMANN, H. J. VAN BEEKHUIZEN, H. TRUM, D. BOLL, H. M. J. WERNER, L. R. C. W. VAN LONKHUIJZEN, R. YIGIT, D. FORSSE, P. O. WITTEVEEN, K. GALAAL, A. VAN GINKEL, E. BIGNOTTI, Vít WEINBERGER (203 Czech Republic, belonging to the institution), S. SWEEGERS, J. R. KROEP, S. CABRERA, M. P. L. M. SNIJDERS, M. A. INDA, A. G. Z. ERIKSSON, C. KRAKSTAD, A. ROMANO, A. VAN DE STOLPE and J. M. A. PIJNENBORG

Edition

American journal of obstetrics and gynecology, St. Louis, C.V. Mosby, 2021, 0002-9378

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30214 Obstetrics and gynaecology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 10.693

RIV identification code

RIV/00216224:14110/21:00123113

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.ajog.2021.05.007

UT WoS

000720311600011

Keywords in English

aromatase inhibitors; estrogen receptor pathway activity; progesterone receptor; progestin therapy

Abstract

V originále

BACKGROUND: Approximately 20% of women with endometrial cancer have advanced-stage disease or suffer from a recurrence. For these women, prognosis is poor, and palliative treatment options include hormonal therapy and chemotherapy. Lack of predictive biomarkers and suboptimal use of existing markers for response to hormonal therapy have resulted in overall limited efficacy. OBJECTIVE: This study aimed to improve the efficacy of hormonal therapy by relating immunohistochemical expression of estrogen and progesterone receptors and estrogen receptor pathway activity scores to response to hormonal therapy. STUDY DESIGN: Patients with advanced or recurrent endometrial cancer and available biopsies taken before the start of hormonal therapy were identified in 16 centers within the European Network for Individualized Treatment in Endometrial Cancer and the Dutch Gynecologic Oncology Group. Tumor tissue was analyzed for estrogen and progesterone receptor expressions and estrogen receptor pathway activity using a quantitative polymerase chain reaction-based messenger RNA model to measure the activity of estrogen receptor-related target genes in tumor RNA. The primary endpoint was response rate defined as complete and partial response using the Response Evaluation Criteria in Solid Tumors. The secondary endpoints were clinical benefit rate and progression-free survival. RESULTS: Pretreatment biopsies with sufficient endometrial cancer tissue and complete response evaluation were available in 81 of 105 eligible cases. Here, 22 of 81 patients (27.2%) with a response had estrogen and progesterone receptor expressions of >50%, resulting in a response rate of 32.3% (95% confidence interval, 20.9-43.7) for an estrogen receptor expression of >50% and 50.0% (95% confidence interval, 35.2-64.8) for a progesterone receptor expression of >50%. Clinical benefit rate was 56.9% for an estrogen receptor expression of >50% (95% confidence interval, 44.9-68.9) and 75.0% (95% confidence interval, 62.2-87.8) for a progesterone receptor expression of >50%. The application of the estrogen receptor pathway test to cases with a progesterone receptor expression of >50% resulted in a response rate of 57.6% (95% confidence interval, 42.1-73.1). After 2 years of follow-up, 34.3% of cases (95% confidence interval, 20-48) with a progesterone receptor expression of >50% and 35.8% of cases (95% confidence interval, 20-52) with an estrogen receptor pathway activity score of >15 had not progressed. CONCLUSION: The prediction of response to hormonal treatment in endometrial cancer improves substantially with a 50% cutoff level for progesterone receptor immunohistochemical expression and by applying a sequential test algorithm using progesterone receptor immunohistochemical expression and estrogen receptor pathway activity scores. However, results need to be validated in the prospective Prediction of Response to Hormonal Therapy in Advanced and Recurrent Endometrial Cancer (PROMOTE) study.

Citovat

WEELDEN, van W. J., R. I. LALISANG, J. BULTEN, K. LINDEMANN, H. J. VAN BEEKHUIZEN, H. TRUM, D. BOLL, H. M. J. WERNER, L. R. C. W. VAN LONKHUIJZEN, R. YIGIT, D. FORSSE, P. O. WITTEVEEN, K. GALAAL, A. VAN GINKEL, E. BIGNOTTI, Vít WEINBERGER, S. SWEEGERS, J. R. KROEP, S. CABRERA, M. P. L. M. SNIJDERS, M. A. INDA, A. G. Z. ERIKSSON, C. KRAKSTAD, A. ROMANO, A. VAN DE STOLPE and J. M. A. PIJNENBORG. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer. American journal of obstetrics and gynecology. St. Louis: C.V. Mosby, 2021, vol. 225, No 4, p. "407.e1"-"407.e16", 16 pp. ISSN 0002-9378. Available from: https://dx.doi.org/10.1016/j.ajog.2021.05.007.

@article{1807760,
   author = {Weelden, van W. J. and Lalisang, R. I. and Bulten, J. and Lindemann, K. and van Beekhuizen, H. J. and Trum, H. and Boll, D. and Werner, H. M. J. and van Lonkhuijzen, L. R. C. W. and Yigit, R. and Forsse, D. and Witteveen, P. O. and Galaal, K. and van Ginkel, A. and Bignotti, E. and Weinberger, Vít and Sweegers, S. and Kroep, J. R. and Cabrera, S. and Snijders, M. P. L. M. and Inda, M. A. and Eriksson, A. G. Z. and Krakstad, C. and Romano, A. and van de Stolpe, A. and Pijnenborg, J. M. A.},
   article_location = {St. Louis},
   article_number = {4},
   doi = {http://dx.doi.org/10.1016/j.ajog.2021.05.007},
   keywords = {aromatase inhibitors; estrogen receptor pathway activity; progesterone receptor; progestin therapy},
   language = {eng},
   issn = {0002-9378},
   journal = {American journal of obstetrics and gynecology},
   title = {Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer},
   url = {https://www.sciencedirect.com/science/article/pii/S0002937821005548?via%3Dihub},
   volume = {225},
   year = {2021}
}

TY  - JOUR
ID  - 1807760
AU  - Weelden, van W. J. - Lalisang, R. I. - Bulten, J. - Lindemann, K. - van Beekhuizen, H. J. - Trum, H. - Boll, D. - Werner, H. M. J. - van Lonkhuijzen, L. R. C. W. - Yigit, R. - Forsse, D. - Witteveen, P. O. - Galaal, K. - van Ginkel, A. - Bignotti, E. - Weinberger, Vít - Sweegers, S. - Kroep, J. R. - Cabrera, S. - Snijders, M. P. L. M. - Inda, M. A. - Eriksson, A. G. Z. - Krakstad, C. - Romano, A. - van de Stolpe, A. - Pijnenborg, J. M. A.
PY  - 2021
TI  - Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer
JF  - American journal of obstetrics and gynecology
VL  - 225
IS  - 4
SP  - "407.e1"-"407.e16"
EP  - "407.e1"-"407.e16"
PB  - C.V. Mosby
SN  - 00029378
KW  - aromatase inhibitors
KW  - estrogen receptor pathway activity
KW  - progesterone receptor
KW  - progestin therapy
UR  - https://www.sciencedirect.com/science/article/pii/S0002937821005548?via%3Dihub
N2  - BACKGROUND: Approximately 20% of women with endometrial cancer have advanced-stage disease or suffer from a recurrence. For these women, prognosis is poor, and palliative treatment options include hormonal therapy and chemotherapy. Lack of predictive biomarkers and suboptimal use of existing markers for response to hormonal therapy have resulted in overall limited efficacy. OBJECTIVE: This study aimed to improve the efficacy of hormonal therapy by relating immunohistochemical expression of estrogen and progesterone receptors and estrogen receptor pathway activity scores to response to hormonal therapy. STUDY DESIGN: Patients with advanced or recurrent endometrial cancer and available biopsies taken before the start of hormonal therapy were identified in 16 centers within the European Network for Individualized Treatment in Endometrial Cancer and the Dutch Gynecologic Oncology Group. Tumor tissue was analyzed for estrogen and progesterone receptor expressions and estrogen receptor pathway activity using a quantitative polymerase chain reaction-based messenger RNA model to measure the activity of estrogen receptor-related target genes in tumor RNA. The primary endpoint was response rate defined as complete and partial response using the Response Evaluation Criteria in Solid Tumors. The secondary endpoints were clinical benefit rate and progression-free survival. RESULTS: Pretreatment biopsies with sufficient endometrial cancer tissue and complete response evaluation were available in 81 of 105 eligible cases. Here, 22 of 81 patients (27.2%) with a response had estrogen and progesterone receptor expressions of >50%, resulting in a response rate of 32.3% (95% confidence interval, 20.9-43.7) for an estrogen receptor expression of >50% and 50.0% (95% confidence interval, 35.2-64.8) for a progesterone receptor expression of >50%. Clinical benefit rate was 56.9% for an estrogen receptor expression of >50% (95% confidence interval, 44.9-68.9) and 75.0% (95% confidence interval, 62.2-87.8) for a progesterone receptor expression of >50%. The application of the estrogen receptor pathway test to cases with a progesterone receptor expression of >50% resulted in a response rate of 57.6% (95% confidence interval, 42.1-73.1). After 2 years of follow-up, 34.3% of cases (95% confidence interval, 20-48) with a progesterone receptor expression of >50% and 35.8% of cases (95% confidence interval, 20-52) with an estrogen receptor pathway activity score of >15 had not progressed. CONCLUSION: The prediction of response to hormonal treatment in endometrial cancer improves substantially with a 50% cutoff level for progesterone receptor immunohistochemical expression and by applying a sequential test algorithm using progesterone receptor immunohistochemical expression and estrogen receptor pathway activity scores. However, results need to be validated in the prospective Prediction of Response to Hormonal Therapy in Advanced and Recurrent Endometrial Cancer (PROMOTE) study.
ER  -

WEELDEN, van W. J., R. I. LALISANG, J. BULTEN, K. LINDEMANN, H. J. VAN BEEKHUIZEN, H. TRUM, D. BOLL, H. M. J. WERNER, L. R. C. W. VAN LONKHUIJZEN, R. YIGIT, D. FORSSE, P. O. WITTEVEEN, K. GALAAL, A. VAN GINKEL, E. BIGNOTTI, Vít WEINBERGER, S. SWEEGERS, J. R. KROEP, S. CABRERA, M. P. L. M. SNIJDERS, M. A. INDA, A. G. Z. ERIKSSON, C. KRAKSTAD, A. ROMANO, A. VAN DE STOLPE and J. M. A. PIJNENBORG. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer. \textit{American journal of obstetrics and gynecology}. St. Louis: C.V. Mosby, 2021, vol.~225, No~4, p.~''407.e1''-''407.e16'', 16 pp. ISSN~0002-9378. Available from: https://dx.doi.org/10.1016/j.ajog.2021.05.007.

Detailed Information on Publication Record